Alpa Laboratories Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹920.53 million
- Book Value:
- Revenue TTM:
- ₹820.97 million
- Operating Margin TTM:
- Gross Profit TTM:
- ₹306.92 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Alpa Laboratories Limited had its IPO on under the ticker symbol 532878.
The company operates in the Other sector and Other industry. Alpa Laboratories Limited has a staff strength of 391 employees.
Shares of Alpa Laboratories Limited opened at ₹78.57 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹72.24 - ₹78.88, and closed at ₹73.22.
This is a -6.16% slip from the previous day's closing price.
A total volume of 54,821 shares were traded at the close of the day’s session.
In the last one week, shares of Alpa Laboratories Limited have slipped by -7.81%.
Alpa Laboratories Limited's Key Ratios
Alpa Laboratories Limited has a market cap of ₹920.53 million, indicating a price to book ratio of 0.7746 and a price to sales ratio of 0.948.
In the last 12-months Alpa Laboratories Limited’s revenue was ₹820.97 million with a gross profit of ₹306.92 million and an EBITDA of ₹48.04 million. The EBITDA ratio measures Alpa Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alpa Laboratories Limited’s operating margin was 1.37% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Alpa Laboratories Limited’s quarterly earnings growth was a positive 163.8% while revenue growth was a negative 19.2%.
Alpa Laboratories Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹1.848 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alpa Laboratories Limited’s profitability.
Alpa Laboratories Limited stock is trading at a EV to sales ratio of 0.4128 and a EV to EBITDA ratio of 4.4449. Its price to sales ratio in the trailing 12-months stood at 0.948.
Alpa Laboratories Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.67 billion
- Total Liabilities
- ₹305.71 million
- Operating Cash Flow
- ₹11.69 million
- Capital Expenditure
- ₹11.28 million
- Dividend Payout Ratio
Alpa Laboratories Limited ended 2023 with ₹1.67 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.67 billion while shareholder equity stood at ₹1.35 billion.
Alpa Laboratories Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹305.71 million in other current liabilities, 210406000.00 in common stock, ₹1.14 billion in retained earnings and ₹834000.00 in goodwill. Its cash balance stood at ₹88.14 million and cash and short-term investments were ₹839.98 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹23.04 million.
Alpa Laboratories Limited’s total current assets stands at ₹1.52 billion while long-term investments were ₹0 and short-term investments were ₹738.44 million. Its net receivables were ₹467.33 million compared to accounts payable of ₹0 and inventory worth ₹126.41 million.
In 2023, Alpa Laboratories Limited's operating cash flow was ₹11.69 million while its capital expenditure stood at ₹11.28 million.
Comparatively, Alpa Laboratories Limited paid ₹0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Alpa Laboratories Limited stock is currently trading at ₹73.22 per share. It touched a 52-week high of ₹85.6 and a 52-week low of ₹85.6. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹73.66 and 200-day moving average was ₹64.15 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5666.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Alpa Laboratories Limited
Similar Industry Stocks (Other)
Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including liquid injections, dry powder injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human use; and boluses, injections, and intra-mammary infusions for veterinary use. The company provides its products in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, anti protozoans, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. Alpa Laboratories Limited sells its products through distributors, as well as retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to various countries in South and Central America, Africa, and Asia, including CIS countries comprising Russia, Ukraine, Kazakhstan, etc. Alpa Laboratories Limited was incorporated in 1988 and is based in Indore, India.